FDA Approves Inotuzumab Ozogamicin (Besponsa) for ALL FDA Approves Inotuzumab Ozogamicin (Besponsa) for ALL
The new drug is for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). These patients have a very poor prognosis.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer & Oncology | Health | Hematology | Leukemia